OverviewSuggest Edit

Our vision is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet needs.
GW is developing a portfolio of cannabinoid medicines, including Sativex for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.

... Show more
TypePublic
Founded1998
HQHiston, GB
Websitegwpharm.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2017)496
Job Openings43
Revenue (FY, 2017)£8.2 M(-20%)
Share Price (Feb 2019)$150.5

GW Pharmaceuticals Office Locations

GW Pharmaceuticals has offices in Histon, London and Carlsbad
Histon, GB (HQ)
Vision Park
London, GB
1 Cavendish Pl
Carlsbad, US
210 5800 Armada Dr
Show all (3)
Report incorrect company information

GW Pharmaceuticals Financials and Metrics

GW Pharmaceuticals Revenue

GW Pharmaceuticals's revenue was reported to be £8.24 m in FY, 2017
GBP

Revenue (FY, 2017)

8.2m

Gross profit (FY, 2017)

4.7m

Gross profit margin (FY, 2017), %

57%

Net income (FY, 2017)

(131.7m)

EBITDA (FY, 2017)

(147.8m)

EBIT (FY, 2017)

(153.3m)

Market capitalization (15-Feb-2019)

4.6b

Closing stock price (15-Feb-2019)

150.5

Cash (30-Sep-2017)

241.2m
GW Pharmaceuticals's current market capitalization is $4.6 b.
GBPFY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.0m3.1m2.0m5.7m11.8m24.1m30.7m29.6m33.1m27.3m30.0m28.5m10.3m8.2m

Revenue growth, %

10%(5%)(64%)

Cost of goods sold

82.0k277.0k254.0k249.0k433.0k752.0k1.3m839.0k1.3m2.1m2.6m2.7m3.5m

Gross profit

3.0m1.7m5.4m11.5m23.7m29.9m28.3m32.3m26.0m28.0m25.9m7.6m4.7m
GBPFY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

25.7m20.2m32.0m17.8m13.0m5.4m21.0m14.1m20.6m25.2m28.3m29.3m38.1m164.5m234.9m374.4m241.2m

Accounts Receivable

579.0k240.0k204.0k811.0k1.2m1.5m758.0k621.0k612.0k373.0k778.0k1.0m

Inventories

656.0k695.0k535.0k503.0k780.0k1.4m3.5m4.7m4.8m4.8m4.2m4.2m

Current Assets

26.6m21.5m34.2m20.2m15.8m24.9m24.3m17.1m22.3m27.2m32.0m35.3m47.4m176.4m255.1m404.5m276.7m
GBPFY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(6.9m)(11.2m)(8.1m)(13.7m)(7.5m)(11.9m)(10.9m)(8.2m)1.5m4.6m2.7m2.5m(4.5m)(14.7m)(44.6m)(63.7m)(131.7m)

Cash From Operating Activities

6.3m10.4m8.6m16.4m10.0m3.3m(1.5m)7.4m1.2m4.3m2.4m1.8m(7.5m)(12.6m)(46.5m)(84.6m)(110.2m)

Cash From Financing Activities

30.5m4.4m19.3m108.0k2.8m8.1m62.0k104.0k6.3m628.0k1.4m73.0k18.3m144.3m128.4m206.8m(2.1m)

Net Change in Cash

1.2m279.0k1.1m1.7m1.7m2.5m2.5m6.9m6.5m4.6m3.1m814.0k8.7m124.5m64.2m113.5m(127.6m)
GBPY, 2017

Revenue/Employee

16.6k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

GW Pharmaceuticals News and Updates

Global Epilepsy Drugs Market Report 2019 Featuring Eisai, UCB, H. Lundbeck A/S, and GW Pharmaceuticals

DUBLIN, Feb. 12, 2019 /PRNewswire/ -- The "Epilepsy Drugs Market by Country (US, UK, France, etc), Drugs (Vimpat, Keppra, Sabril, Onfi, etc), Treatment Drugs Generation (First, Second, Third), Companies & Forecast" report has been added to ResearchAndMarkets.com's offering. The global...

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending 31 December 2018 and Host Conference Call on 26 February 2019

LONDON, Feb. 07, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 26 February, 2019 its fi…

GW Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference

LONDON and CARLSBAD, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced tha…

GW Pharmaceuticals stock ticks down after revenue miss

GW Pharmaceuticals PLC shares fell less than 1% in the extended session Tuesday after the company missed revenue expectations. The company reported fiscal fourth-quarter net losses of $79.9 million, or 23 cents a share, compared with $53.9 million, or 18 cents a share, in the year-ago period. Reven…

GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress

- Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine launched in the U.S. - - Conference call today at 4:30 p.m. EST -

Food and Drug Administration (FDA) Approval of GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences' EPIDIOLEX® (cannabidiol) CV Marks First Drug Approval and Scheduling Decision Supported by Analgesic Solutions' MADDERS® Systemwdxefcqufszuzezftuxetqsqxt

WAYLAND, Mass., Oct. 22, 2018 /PRNewswire/ -- Analgesic Solutions LLC is proud to announce Greenwich Bioscience's EPIDIOLEX marks the first medication approval and scheduling decision supported by data from the Misuse, Abuse and Diversion Drug Event Reporting System (MADDERS®). EPIDIOLEX...
Show more
Report incorrect company information

GW Pharmaceuticals Company Life and Culture

Report incorrect company information

GW Pharmaceuticals Frequently Asked Questions

  • When was GW Pharmaceuticals founded?

    GW Pharmaceuticals was founded in 1998.

  • How many employees does GW Pharmaceuticals have?

    GW Pharmaceuticals has 496 employees.

  • What is GW Pharmaceuticals revenue?

    Latest GW Pharmaceuticals annual revenue is £8.2 m.

  • What is GW Pharmaceuticals revenue per employee?

    Latest GW Pharmaceuticals revenue per employee is £16.6 k.

  • Who are GW Pharmaceuticals competitors?

    Competitors of GW Pharmaceuticals include STERIS, BioScrip and Cytokinetics.

  • Where is GW Pharmaceuticals headquarters?

    GW Pharmaceuticals headquarters is located at Vision Park, Histon.

  • Where are GW Pharmaceuticals offices?

    GW Pharmaceuticals has offices in Histon, London and Carlsbad.

  • How many offices does GW Pharmaceuticals have?

    GW Pharmaceuticals has 3 offices.